Last $29.16 USD
Change Today +1.53 / 5.54%
Volume 485.6K
INSY On Other Exchanges
As of 5:20 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

insys therapeutics inc (INSY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $57.91
52 Week Low
07/30/13 - $10.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

insys therapeutics inc (INSY) Related Businessweek News

No Related Businessweek News Found

insys therapeutics inc (INSY) Details

Insys Therapeutics, Inc., a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. It offers its Subsys through its incentive-based commercial sales force. The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Insys Therapeutics, Inc. was incorporated in 1990 and is headquartered in Chandler, Arizona.

202 Employees
Last Reported Date: 03/5/14
Founded in 1990

insys therapeutics inc (INSY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $337.9K
Compensation as of Fiscal Year 2013.

insys therapeutics inc (INSY) Key Developments

Insys Therapeutics Updates Timing of NDA for Dronabinol Oral Solution

Insys Therapeutics, Inc. announced the successful completion of a human abuse study for Dronabinol Oral Solution, its proprietary, orally administered liquid formulation of the synthetic cannabinoid dronabinol in development for the treatment of chemotherapy induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. Insys completed the clinical portion of the New Drug Application (NDA) for Dronabinol Oral Solution during the third quarter of 2013, as previously announced. The human abuse study was required by the U.S. Drug Enforcement Agency (DEA) for scheduling classification purposes. The Company now intends to file this NDA in the third quarter of 2014. Dronabinol is currently available only in a soft gelatin capsule form. According to Symphony Health Solutions, total prescriptions of Dronabinol grew 5% in 2013 as compared to 2012. While the capsule is available in only three strengths (2.5 mg, 5 mg and 10 mg), Insys' Dronabinol Oral Solution presents an opportunity for physicians to titrate more effectively. Insys is committed to Cannabinoid research and has an advanced manufacturing facility approved by FDA and DEA to produce pharmaceutical grade active pharmaceutical ingredient (API) Cannabinoids. Insys recently received Orphan Drug designation for its pharmaceutical Cannabidiol (CBD) candidate for Lennox-Gastaut Syndrome and Dravet Syndrome in pediatric populations, and is aggressively pursuing development of these indications.

Insys Therapeutics, Inc. Reaffirms Revenue Guidance for the Second Quarter Ending June 30, 2014

Insys Therapeutics, Inc. reaffirms revenue guidance for the second quarter ending June 30, 2014. For the period, the company reaffirmed its revenue guidance for the second quarter ending June 30, 2014. Revenue from sales of Subsys (Fentanyl Sublingual Spray) is expected to exceed $52.0 million for the quarter, as compared with $18.5 million during the second quarter of 2013.

INSYS Therapeutics, Inc. Receives FDA Orphan Drug Designation for its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome

Insys Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Lennox-Gastaut Syndrome, a rare pediatric-onset epilepsy. In addition to Lennox-Gastaut Syndrome, Insys plans to develop treatments for another rare form of pediatric epilepsy, Dravet Syndrome. Insys is also evaluating the potential use of pharmaceutical CBD in several additional indications, including: adult epilepsy; chemotherapy-induced peripheral neuropathy; addiction in cocaine, heroin and opioids; and glioblastoma. Insys intends to pursue orphan drug designation for other indications that may qualify. Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat rare diseases or conditions affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, as well as certain financial incentives that can help support its development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSY:US $29.16 USD +1.53

INSY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $5.89 USD -0.293
Array BioPharma Inc $4.18 USD -0.10
BioDelivery Sciences International Inc $12.81 USD +0.20
Depomed Inc $11.74 USD -0.03
Spectrum Pharmaceuticals Inc $7.05 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation INSY Industry Range
Price/Earnings 19.6x
Price/Sales 7.1x
Price/Book 9.7x
Price/Cash Flow 19.7x
TEV/Sales 6.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSYS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at